Cargando…

Biomarkers as Predictors of Recurrence following Curative Resection for Pancreatic Ductal Adenocarcinoma: A Review

Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osayi, Sylvester N., Bloomston, Mark, Schmidt, Carl M., Ellison, E. Christopher, Muscarella, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094702/ https://www.ncbi.nlm.nih.gov/pubmed/25050350 http://dx.doi.org/10.1155/2014/468959

Ejemplares similares

Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection
por: Murakawa, Masaaki, et al.
Publicado: (2023)

Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma
por: Katsuta, Eriko, et al.
Publicado: (2020)

Pancreatectomy for non-pancreatic malignancies results in improved survival after R0 resection
por: Varker, Kimberly A, et al.
Publicado: (2007)

Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival
por: Morales-Oyarvide, Vicente, et al.
Publicado: (2017)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection
por: Murakawa, Masaaki, et al.
Publicado: (2019)

Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma
por: Rittmann, Marie-Claire, et al.
Publicado: (2021)

Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection
por: Sugawara, Toshitaka, et al.
Publicado: (2021)

Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017)

Survival Prediction after Curative Resection of Pancreatic Ductal Adenocarcinoma by Imaging-Based Intratumoral Necrosis
por: Kim, Hokun, et al.
Publicado: (2022)

Predictive Model of Early Death of Resectable Pancreatic Ductal Adenocarcinoma After Curative Resection: A SEER-Based Study
por: Liu, Weikang, et al.
Publicado: (2022)

Adenocarcinoma of the ampulla of Vater: predictors of survival and recurrence after curative radical resection
por: Kim, Kang Jae, et al.
Publicado: (2011)

Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection
por: Pu, Ning, et al.
Publicado: (2017)

Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study
por: Zou, Siyi, et al.
Publicado: (2022)

Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Dopico, Pablo J., et al.
Publicado: (2022)

Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma
por: Shimagaki, Tomonari, et al.
Publicado: (2023)

Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy
por: Murata, Yasuhiro, et al.
Publicado: (2022)

Three Curative Pancreatectomies for the Metachronous Appearance of Pancreatic Invasive Ductal Adenocarcinoma
por: Miyagawa, Yusuke, et al.
Publicado: (2020)

Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma
por: Słodkowski, Maciej, et al.
Publicado: (2023)

Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
por: Lee, Seung Jae, et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Surgical Resection or Ablation for Recurrent Pancreatic Ductal Adenocarcinoma: An Analysis of Oncologic Outcomes According to the Recurrence Type
por: Lee, Boram, et al.
Publicado: (2021)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Ratnayake, Bathiya, et al.
Publicado: (2020)

Analysis of preoperative risk factors for early recurrence after curative pancreatoduodenectomy for resectable pancreatic adenocarcinoma
por: Burasakarn, Pipit, et al.
Publicado: (2022)

Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection
por: Flis, Vojko, et al.
Publicado: (2016)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
por: Li, Shuo, et al.
Publicado: (2019)

Successful resection of port site recurrence of pancreatic ductal adenocarcinoma after laparoscopic distal pancreatectomy
por: Aida, Takashi, et al.
Publicado: (2023)

Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma
por: Llop, Esther, et al.
Publicado: (2018)

Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Kim, Hongbeom, et al.
Publicado: (2020)

Perineural Invasion in Pancreatic Ductal Adenocarcinoma (PDAC): A Saboteur of Curative Intended Therapies?
por: Felsenstein, Matthäus, et al.
Publicado: (2022)

Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
por: Feigin, Michael E., et al.
Publicado: (2017)

The enigmatic helicase DHX9 as a candidate prognostic biomarker for resected pancreatic ductal adenocarcinoma
por: Chen, Le-gao, et al.
Publicado: (2022)

Reappraise role of lymph node status in patterns of recurrence following curative resection of gastric adenocarcinoma
por: Tang, Yihui, et al.
Publicado: (2021)

Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
por: Buc, Emmanuel, et al.
Publicado: (2014)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
por: Lohneis, Philipp, et al.
Publicado: (2018)

The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition
por: Soweid, Assaad M.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rr9og630ma4jhgk64t30i2dvht